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BSTRACT
Background:
 
Both a recombinant soluble form of the
high-affinity IgE receptor 
 
α
 
 subunit (rsFc
 
ε
 
RI
 
α
 
) and anti-
IgE antibody have been shown to be involved in the
regulation of IgE synthesis. However, the mechanisms
of IgE regulation by two such IgE-binding agents
remain unclear. In the present study, we investigated
whether rsFc
 
ε
 
RI
 
α
 
 and anti-IgE antibody modulated IgE
synthesis in an identical or different manner.
 
Methods:
 
Normal human B cells stimulated with
interleukin (IL)-4 plus anti-CD40 antibody were ana-
lyzed for the regulatory effects of rsFc
 
ε
 
RI
 
α
 
 and anti-
IgE antibody on the expression of C
 
ε
 
 transcipts, the
autocrine production of IL-6 and the induction of
apoptosis.
 
Results:
 
Both rsFc
 
ε
 
RI
 
α
 
 and anti-IgE antibody inhibited
mature C
 
ε
 
 transcription, without affecting germline C
 
ε
 
transcription. In addition, rsFc
 
ε
 
RI
 
α
 
 was effective in
decreasing IL-6 production at a later stage when IgE-
expressing B cells were generated, whereas F(ab
 
′
 
)
 
2
 
,
but not the Fab fragment, of anti-IgE antibody induced
apoptosis in the cells. Although these three agents
almost equally recognized IgE expressed on B cells,
rsFc
 
ε
 
RI
 
α
 
 was unable to induce apoptotic cell death
and the Fab fragment was similarly ineffective in the
regulation of IL-6 production. The addition of IL-6 to
cultures containing rsFc
 
ε
 
RI
 
α
 
 significantly restored its
suppressive effect on IgE synthesis.
 
Conclusions:
 
These results indicate that regulation of
IgE synthesis by rsFc
 
ε
 
RI
 
α
 
 differs from that by anti-IgE
antibody.
 
Key words:
 
 apoptosis, divalent recognition, IgE-bind-
ing agents, IgE-expressing B cells, interleukin-6,
monovalent recognition.
 
I
 
NTRODUCTION
 
It is well known that IgE-binding factors derived from
T cells and anti-IgE antibodies, which target IgE-express-
ing B cells, exert selective effects on the IgE response.
 
1–4
 
We have previously shown that, in addition to anti-IgE
antibodies, a recombinant soluble form of the high-
affinity IgE receptor 
 
α
 
 subunit (rsFc
 
ε
 
RI
 
α
 
), which binds
free IgE with an affinity as high as that of native Fc
 
ε
 
RI,
can modulate IgE synthesis by binding to the surface
IgE on B cells.
 
5
 
 Although the membrane-bound form of
IgE is a common target for such potent IgE-binding
agents, there are some differences in efficacy between
monovalent and divalent recognition. For example, anti-
IgE antibodies, regardless of anaphylactogenic or non-
anaphylactogenic antibodies, are involved in surface
IgE cross-linking-mediated inhibition of IgE synthesis in
human B cell cultures stimulated with interleukin (IL)-4
plus anti-CD40 monoclonal antibody (mAb).
 
4
 
 Support-
ive evidence for this divalent recognition is that F(ab
 
′
 
)
 
2
 
,
but not Fab fragments, of anti-IgE antibodies have an
inhibitory effect. In contrast with the Fab fragment,
rsFc
 
ε
 
RI
 
α
 
 effectively decreases IgE synthesis, possibly via
monovalent recognition, because the stoichiometry for
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the IgE binding of the rsFc
 
ε
 
RI
 
α
 
 has been shown to be
1 : 1.
 
6,7
 
 However, the mechanisms by which rsFc
 
ε
 
RI
 
α
 
and anti-IgE antibodies inhibit IgE synthesis remain
unclear.
Previous investigations have suggested that the differ-
entiation of IgE-expressing B cells into IgE-secreting cells
may be subject to positive or negative regulation by
several different factors.
 
2–4,8–10
 
 Of these factors, one pos-
itive regulating factor is the autocrine production of IL-6,
which provides a late amplification signal for IgE synthe-
sis, whereas a negative regulating factor is the induction
of apoptosis, which may eliminate IgE-expressing B cells.
However, it is presently unknown whether IgE-expressing
B cells respond to a signal delivered through their surface
IgE with decreased IL-6 production or with apoptotic cell
death.
In the present study, we have examined the relative
contributions of rsFc
 
ε
 
RI
 
α
 
 and Fab and F(ab
 
′
 
)
 
2
 
 fragments
of anti-IgE mAb to endogeneous IL-6 production and to
apoptosis induction in IgE-expressing B cells generated
by IL-4 plus anti-CD40 mAb stimulation of normal
human B cells.
 
M
 
ETHODS
 
The rsFc
 
ε
 
RI
 
α
 
 and mouse anti-rsFc
 
ε
 
RI
 
α
 
 mAb (CRA-1,
IgG2b) were the same as described previously.
 
5
 
 The
CRA-1 had no ability to compete with IgE in binding to
rsFc
 
ε
 
RI
 
α
 
. Mouse antihuman IgE mAb (G7-18, IgG1)
was obtained from PharMingen (San Diego, CA, USA).
Although the epitope specificity of G7-18 was not des-
cribed in the attached data sheet, our preliminary
observation that G7-18 induced anaphylactic histamine
release from atopic human peripheral leukocytes revealed
that G7-18 recognizes cytophilic IgE on basophils. The
Fab and F(ab
 
′
 
)
 
2
 
 fragments of G7-18 were prepared
using the IgG1 Fab and F(ab
 
′
 
)
 
2
 
 preparation kit (Pierce
Chemical, Rockford, IL, USA) according to the manufac-
turer’s instructions. The fragments had undetectable
contaminants of the intact antibody, as determined by a
10% non-reducing sodium dodecyl sulfate–polyacrylamide
gel electrophoresis. The ability of G7-18 and its frag-
ments to bind to IgE was determined by flow cytometry
using the Fc
 
ε
 
RI
 
α
 
-expressing transfectant (a T cell hybrid-
oma, MA5.8)-fixed IgE. No significant differences in
binding activity were observed among G7-18 and Fab
and F(ab
 
′
 
)
 
2
 
 fragments when each of them was added to
the transfectant.
 
Cell preparation and cultures
 
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood obtained from
normal healthy adults who had given informed consent
to participate in the study and cytophilic IgE was
removed by treatment with acid buffer, as described
previously.
 
5
 
 Depletion of CD2
 
+
 
, CD14
 
+
 
 and CD56
 
+
 
cells from PBMC was performed using magnetic beads
coated with appropriate mAbs or streptavidin (Dynal,
Oslo, Norway), as described elsewhere.
 
11
 
 The purity of
CD19
 
+
 
 B cells obtained was always > 98% as deter-
mined by flow cytometry. Highly purified B cells were
suspended at a concentration of 1 
 
×
 
 10
 
6
 
 cells/mL in
Iscove’s modified Dulbecco’s medium (Gibco BRL,
Grand Island, NY, USA) supplemented with 10% fetal
calf serum, 2 mmol/L l-glutamine, 50 U/mL penicillin
and 50 
 
µ
 
g/mL streptomycin. Aliquots of the cell suspen-
sion in a total volume of 0.2 mL were cultured in 96-well
round-bottomed plates (Costar, Cambridge, MA, USA)
with or without 2 ng/mL recombinant human IL-4 (Gen-
zyme, Cambridge, MA, USA) plus 1 
 
µ
 
g/mL of an
agonistic mouse antihuman CD40 mAb (EA-5, IgG1;
Ancell, Bayport, MI, USA) for the indicated time periods.
In some experiments, recombinant human IL-6 (Gen-
zyme) at appropriate concentrations was added to the
culture.
 
IgE measurement
 
IgE levels in culture supernatants were measured by an
isotype-specific radioimmunoassay using two different
anti-IgE mAbs, as described previously.
 
5
 
 Although rsFc
 
ε
 
RI
 
α
 
and G7-18 at 1–1000 ng/mL, regardless of their con-
centrations, showed 25–30% inhibition of the assay,
no significant differences were observed within these
ranges when the standard curve was constructed by
calculating least-square lines. For example, these were
log 
 
y
 
 = 1.00 log x – 0.43 (
 
r
 
 = 0.999; vehicle) versus
log 
 
y
 
 = 0.99 log x – 0.58 (
 
r
 
 = 0.999; 1 ng rsFc
 
ε
 
RI
 
α
 
),
log 
 
y
 
 = 1.02 log x – 0.57 (
 
r
 
 = 0.998; 1000 ng rsFc
 
ε
 
RI
 
α
 
),
log 
 
y
 
 = 1.01 log x – 0.54 (
 
r
 
 = 0.998; 1 ng G7-18) and
log 
 
y
 
 = 0.98 log x – 0.59 (
 
r
 
 = 0.997; 1000 ng G7-18).
The Fab and F(ab
 
′
 
)
 
2
 
 fragments of G7-18 gave similar
results. Thus, either rsFcεRIα or G7-18 at the highest
concentration used in the present study was usually
added to the corresponding control supernatant before
the assay. This procedure enabled the exact determina-
tion of IgE levels in the supernatants containing rsFcεRIα
or G7-18, despite entirely different recognition of Fcε
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epitopes. The net synthesis of IgE was calculated by
subtracting the value of preformed IgE released in the
presence of both cycloheximide and puromycin.5,11
Competitive reverse transcription–polymerase 
chain reaction for germline and mature Cε 
transcription
Extraction of total cellular RNA and cDNA synthesis by
reverse transcription (RT) was performed as described
previously.11 Levels of cDNA were quantified by means
of a competitive polymerase chain reaction (PCR) method.12
Germline Cε, mature Cε and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) mimics were constructed
by using a commercial construction kit (Clontech Lab-
oratories, Palo Alto, CA, USA). Briefly, two rounds of
PCR amplification were conducted to construct the
mimics. The first PCR was cycled using two composite
primers according to the manufacturer’s protocol. Each
composite primer had the target germline Cε, mature
Cε or GAPDH gene primer sequence attached to a
short nucleotide stretch of sequence designed to
hybridize to opposite strands of a v-erbB gene frag-
ment. The sequences of composite primers were as
follows: germline Cε, 5′-ATCCACAGGCACCAAAT-
GGACGACCCGCAAGTGAAATCTCCTCCG-3′ and
5′-GCCAGGTCCACCACCAGACAGGTGATCTGT-
CAATGCAGTTTGTAG-3′; mature Cε, 5′-TCGACTTCT-
GGGGCCAAGGGCGCAAGTGAAATCTCCTCCG-3′
and 5′-GCCAGGTCCACCACCAGACAGGTGATCT-
TCGGAGTCAACGGATTTGGTCGCAAGTGAAATCTCC
TCCG-3′ and 5′-CATGTGGGCCATGAGGTCCAC-
CACTCTGTCAATGCAGTTTGTAG-3′. The first PCR
products were amplified in a second round of PCR
with primers specific for germline Cε, mature Cε or
GAPDH to confirm that the PCR mimics obtained had
the gene-specific primer sequences.11 Competitive PCR
was performed using serial 10-fold dilutions of PCR
mimics (competitors) mixed with PCR amplification reac-
tions containing a constant amount of the cDNA sample
(targets). The PCR was cycled under suitable conditions,
as described previously.11 The PCR products were ana-
lyzed by electropheresis on 2% agarose gels and visual-
ized by ethidium bromide staining. The bands of targets
and competitors were scanned and quantified using the
Multianalyst hardware and software system (Bio-Rad
Laboratories, Hercules, CA, USA). The results obtained
were expressed as zepto mol/µg RNA for germline or
mature Cε and amol/µg RNA for GAPDH.
Detection of membrane-bound IgE
Cells trapping rsFcεRIα via their surface IgE were
reacted with biotinylated CRA-1 and phycoerythrin (PE)-
conjugated streptavidin, as described previously.5 With
regard to anti-IgE mAb binding to surface IgE, cells were
incubated with biotinylated Fab or F(ab′)2 fragment of
G7-18 (1 µg) for 2 h at 4°C, followed by incubation
with PE-conjugated streptavidin for 30 min. In each
experiment, an isotype-matched control mAb or its
fragment was used for negative staining. Stained cells
were analyzed by flow cytometry on a FACScan (Becton
Dickinson, San Jose, CA, USA) using a gate for lym-
phocytes. Fluorescence data were collected by using
logarithmic amplification.
Apoptosis measurements
Detection of apoptotic cells was performed by using a
commercially available apoptosis detection kit (Medical
& Biological Laboratories, Nagoya, Japan) based on
the terminal deoxynucleotidyl transferase (TdT)-mediated
deoxyuridine 5′-triphosphate (dUTP)-biotin nick end-
labeling method (TUNEL).13 Briefly, cells were fixed with
4% paraformaldehyde, followed by permeabilization
with 70% ethanol. After washing, reaction buffer con-
taining TdT and fluorescein isothiocyanate (FITC)-labeled
dUTP was added to the cell pellet in order to enable
in situ visualization of DNA fragmentation at the single
cell level. Fluorescein isothiocyanate-labeled dUTP alone
was used for negative staining. Stained cells were ana-
lyzed by flow cytometry. Cells in the low forward scatter/
high side scatter subpopulation were apoptotic, as
described in detail elsewhere.14
IL-6 measurement
Quantification of IL-6 present in culture supernatants
was determined using a commercial ELISA kit (BioSource
International, Camarillo, CA, USA). This assay was not
affected by the addition of rsFcεRIα or G7-18 at any
concentration.
Statistical analysis
Paired t-test was used to determine the significance of
the results.
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RESULTS
Inhibitory effect of rsFcεRIα and G7-18 on IgE 
synthesis
B cells from five different donors were stimulated in
the absence or presence of rsFcεRIα or G7-18 at
1–1000 ng/mL for 14 days with IL-4 plus anti-CD40
mAb. As shown in Fig. 1, both rsFcεRIα and G7-18
induced a concentration-dependent inhibition of IgE
synthesis and the maximal inhibition was approximately
the same for 100 ng/mL rsFcεRIα and 1000 ng/mL
G7-18. Their effects on germline and mature Cε trans-
cription were further investigated using RNA from B cells
that had been stimulated for 12 days. A representative
result of competitive RT-PCR is depicted in Fig. 2a. The
results obtained from three different donors are sum-
marized in Fig. 2b. Both rsFcεRIα (100 ng/mL) and
G7-18 (1000 ng/mL) induced marked inhibition of
mature Cε transcription, without affecting germline Cε
transcription. These data are in keeping with previous
reports.4,5
Binding of rsFcεRIα and G7-18 to
IgE-expressing B cells
Both rsFcεRIα and G7-18 were examined for their
capacity to bind to IgE expressed on B cells. For this
purpose, B cells were stimulated for 5 days with IL-4 plus
anti-CD40 mAb and were then analyzed by flow cyt-
ometry. As shown in Fig. 3, surface IgE expression was
detected on 12.7 ± 1.5% (mean ± SEM; n = 3) stimu-
lated cells when rsFcεRIα was used. Also, G7-18 and its
Fab and F(ab′)2 fragments almost equally recognized
surface IgE. In each assay, surface IgE started to be
expressed between 3 and 5 days after stimulation,
reached a peak level at 5 days and rapidly declined
thereafter (data not shown). Nevertheless, the Fab frag-
ment (330 ng/mL) adjusted to the equal molar concen-
tration of the intact antibody (1000 ng/mL), unlike the
F(ab′)2 fragment (670 ng/mL) or rsFcεRIα (100 ng/mL),
was ineffective in the inhibition of IgE synthesis (Fig. 4).
The results obtained with G7-18 confirmed the previous
finding4 that inhibition of IgE synthesis by anti-IgE anti-
bodies, irrespective of their epitope specificity, requires
divalent recognition of surface IgE and demonstrate that
surface IgE binding does not necessarily lead to decreased
IgE synthesis.
Effect of rsFcεRIα and G7-18 on apoptosis
To elucidate the cellular mechanisms by which rsFcεRIα
and G7-18 inhibit IgE synthesis, we first investigated
whether surface IgE-mediated apoptosis of B cells was
inducible. For this purpose, B cells were cultured in the
absence or presence of rsFcεRIα (100 ng/mL), G7-18
(1000 ng/mL), the Fab fragment (330 ng/mL) or the
F(ab′ )2 fragment (670 ng/mL) with IL-4 plus anti-CD40
mAb. After 6 days, apoptotic cells were analyzed by
flow cytometry using TdT and FITC-labeled dUTP. A
representative result of three experiments is shown in
Fig. 5. Although there were no significant differences
in the percentage of apoptotic cells among medium
(27.3 ± 1.5%), rsFcεRIα (28.6 ± 2.3%) and the Fab
fragment (26.9 ± 1.9%), the F(ab′)2 fragment (34.7 ± 1.6%)
and G7-18 (35.2 ± 1.8%) induced significant cell death
by apoptosis (P < 0.05). This result implies that, despite
the net induction of apoptosis in no more than 7% of
stimulated cells, approximately 50% of the IgE-express-
ing B cells generated at a rate of approximately 13%
Fig. 1 Inhibitory effect of a recombinant soluble form of the
high-affinity IgE receptor α subunit (rsFcεRIα) and G7-18 on IgE
synthesis. B cells were stimulated in the absence () or presence
of rsFcεRIα ( ) or G7-18 ( ) at 1–1000 ng/mL with interleukin-
4 plus anti-CD40 antibody for 14 days. Control culture super-
natants were supplemented with rsFcεRIα or G7-18 before the
assay. Net IgE synthesis was assessed by subtracting the value
of preformed IgE. The mean (± SEM) IgE levels in control cul-
tures were 27.1 ± 8.9 ng/mL. Results are expressed in terms of
percent change (mean ± SEM of five different experiments, each
performed in triplicate). *P < 0.05 compared with control. Un-
like G7-18, an isotype-matched control antibody had no inhib-
itory effect on IgE synthesis (data not shown).
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(see Fig. 3) fell into apoptosis following surface IgE
cross-linking.
Effect of rsFcεRIα and G7-18 on IL-6 
production
Next, we addressed whether rsFcεRIα and G7-18 could
regulate the autocrine production of IL-6. Culture super-
natants from B cells stimulated in the absence or
presence of rsFcεRIα(100 ng/mL) or Fab (330 ng/mL)
and F(ab′ )2 (670 ng/mL) of G7-18 with IL-4 plus anti-
CD40 mAb were harvested 1–10 days post-stimulation
and were analyzed for secreted IL-6. Figure 6 shows the
results obtained with three different donors who were
high responders for both IgE and IL-6 production. In
control cultures, IL-6 started to be produced during
1 and 3 days after stimulation and gradually increased
afterwards. It was found that rsFcεRIα was effective in
decreasing IL-6 levels produced at 5–10 days after
stimulation, but not at 1–3 days. A similar result was
obtained with F(ab′ )2 but not Fab fragment of G7-18
capable of inducing apoptosis in IgE-expressing B cells.
This was most likely due to apoptotic cell induction. In
contrast, the suppressive effect of rsFcεRIα on IgE
synthesis, when assessed at 14 days after stimulation,
was significantly restored by adding IL-6 (300–1000 pg/
mL) at the onset of cell culture, although this restoration
was incomplete (Fig. 7). In contrast, inhibition of IgE
synthesis by the F(ab′ )2 fragment was not restored, even
by the addition of IL-6. These results showed that, unlike
G7-18, rsFcεRIα was, to some extent, involved in
regulating the IL-6-dependent differentiation of IgE-
expressing B cells into IgE-secreting cells.
Fig. 2 Effect of a recombinant soluble form of the high-affinity IgE receptor α subunit (rsFcεRIα) and G7-18 on germline and
mature Cε transcription. B cells were stimulated in the absence or presence of rsFcεRIα (100 ng/mL) or G7-18 (1000 ng/mL) with
interleukin-4 plus anti-CD40 antibody for 12 days. After extraction of total cellular RNA, competitive reverse transcription–polymerase
chain reaction (PCR) analysis was performed as described in Methods. (a) cDNA levels for germline Cε, mature Cε and GAPDH in
a donor. Each lane shows progressive 10-fold increments of competitor DNA spiked into the PCR tube with a constant amount of
target cDNA. Arrows indicate a target/competitor ratio of 1.0. (b) Image data were converted to digital values (zepto mol or amol/µg
total RNA) by using computer software. Results represent the mean ± SEM of three different experiments, each performed in triplicate.
*P < 0.01 compared with control.
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DISCUSSION
The present study shows that, in normal human B cell
cultures stimulated with IL-4 plus anti-CD40 mAb, rsFcεRIα
decreases IL-6 production by IgE-expressing B cells,
possibly via monovalent recognition, whereas G7-18,
an anti-IgE mAb, induces apoptosis in the cells through
surface IgE cross-linking. The decrease in IL-6 secretion
is of significance because the addition of IL-6 signifi-
cantly restored the suppressive effect of rsFcεRIα on IgE
Fig. 3 Binding of a recombinant soluble form of the high-affinity IgE receptor α subunit (rsFcεRIα) and G7-18 to surface IgE. B
cells were stimulated with interleukin-4 plus anti-CD40 antibody for 5 days. Cells were incubated either with rsFcεRIα or with bio-
tinylated G7-18 or its Fab or F(ab′)2 fragment. Cells trapping rsFcεRIα were reacted with biotinylated CRA-1, followed by incubation
with phycoerythrin (PE)-conjugated streptavidin. Cells trapping the biotinylated antibody were incubated with PE-conjugated strepta-
vidin. In each experiment, background staining was obtained by incubating cells with an isotype-matched control antibody or its
fragment. Stained cells were analyzed by flow cytometry. Results are representative of three experiments.
Fig. 4 Effect of a recombinant
soluble form of the high-affinity IgE
receptor α subunit (rsFcεRIα) and
G7-18 on IgE synthesis. B cells were
stimulated in the absence or pres-
ence of rsFcεRIα (100 ng/mL), G7-
18 (1000 ng/mL), the Fab fragment
(330 ng/mL) or the F(ab′)2 fragment
(670 ng/mL) with interleukin-4 plus
anti-CD40 antibody for 14 days.
Control culture supernatants were
supplemented with rsFcεRIα or G7-
18 before the assay. Net IgE values
represent the mean ± SEM of four
different experiments, each per-
formed in triplicate. *P < 0.05 com-
pared with control.
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Fig. 5 Effect of a recombinant soluble form of the high-affinity IgE receptor α subunit (rsFcεRIα) and G7-18 on apoptosis. B cells
were cultured in the absence or presence of rsFcεRIα (100 ng/mL), G7-18 (1000 ng/mL), the Fab fragment (330 ng/mL) or the
F(ab′)2 fragment (670 ng/mL) with interleukin-4 plus anti-CD40 antibody for 6 days. Apoptotic cells, which were identified as the
low forward scatter/high side scatter subpopulation (R1), were stained with terminal deoxynucleotidyl transferase plus fluorescein
isothiocyanate (FITC)-labeled deoxyuridine 5′-triphosphate (dUTP). Background staining was obtained by incubating cells with
FITC-labeled dUTP (M1). Apoptotic cells (M2) in total B cells were analyzed by flow cytometry. Results are representative of three
experiments.
Fig. 6 Effect of a recombinant soluble form of the high-affinity
IgE receptor α subunit (rsFcεRIα) and G7-18 on the autocrine
production of interleukin (IL)-6. B cells were cultured in the
absence () or presence of rsFcεRIα (100 ng/mL; ), Fab
(330 ng/mL; ) or F(ab′ )2 (670 ng/mL; ) of G7-18 with IL-4
plus anti-CD40 antibody for up to 10 days. Culture superna-
tants were harvested at the indicated time points and analyzed
for IL-6 levels. Results represent the mean ± SEM of three differ-
ent experiments, each performed in triplicate. *P < 0.05 com-
pared with control.
Fig. 7 Effect of addition of interleukin (IL)-6 on a recombinant
soluble form of the high-affinity IgE receptor α subunit (rsFcε−
RIα)- or G7-18-induced inhibition of IgE synthesis. B cells were
stimulated with IL-4 plus anti-CD40 antibody for 14 days. Either
rsFcεRIα (100 ng/mL; ) or F(ab′ )2 fragment (670 ng/mL; )
of G7-18 mixed with or without IL-6 was added at the onset of
the cell culture. Control culture supernatants were supplement-
ed with rsFcεRIα or the F(ab′ )2 fragment before the assay. Net
IgE values represent the mean ± SEM of three different experi-
ments, each performed in triplicate.*P < 0.05 compared with
the culture containing rsFcεRIα alone.
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synthesis. Evidence that the induction of apoptosis is
specific for divalent recognition is that F(ab′ )2, but not
the Fab fragment of G7-18, was effective. These find-
ings provide the explanation for the difference between
mechanisms for rsFcεRIα- or anti-IgE mAb-induced inhi-
bition of IgE synthesis.
Recombinant soluble FcεRIα is involved in the surface
IgE-mediated attenuation of IL-6 production. Indeed,
rsFcεRIα was able to decrease IL-6 levels produced at a
later stage when IgE-expressing B cells started to be gen-
erated without affecting IL-6 production at an early stage.
The involvement of the autocrine production of IL-6 is
supported by previous reports that showed that a neutral-
izing anti-IL-6 antibody inhibited the T cell-independent
induction of IgE synthesis by IL-4 plus anti-CD40 mAb8
and that these two stimuli synergized for the activation of
nuclear factor-κB, which regulates IL-6 transcription and
production.9 However, IL-6 transcription was not affected
by rsFcεRIα because its induction reached a peak level at
an early stage of B cell activation (data not shown). In
contrast, unlike rsFcεRIα, neither IL-6 production nor IgE
synthesis was inhibited by the Fab fragment of anti-IgE
mAb. This result indicates that simple monovalent recog-
nition of surface IgE does not necessarily contribute to
decreased IL-6 production and suggests that the signal
provided exclusively via surface IgE trapping rsFcεRIα
may be critical in regulating functional IL-6 secretion.
Furthermore, the observation that the suppressive effect
of rsFcεRIα on IgE synthesis could be significantly, but
incompletely, restored by the addition of IL-6 suggests
that IL-6-independent yet unidentified events also may be
involved in the regulation of IgE synthesis. Although the
FcεRI binding site has been shown to be located more to
the beginning of the Cε3 domain of IgE,15,16 no amino
acid replacements within this fragment have been
obtained.17,18 It therefore seems unlikely that functional
polymorphisms exist within the Cε3 gene that may alter
the rsFcεRIα–surface IgE interaction. Although it is not
known whether the binding of rsFcεRIα to IgE-expressing
B cells leads to conformational changes in surface IgE for
signal transduction that are functionally associated with
the selective modulation of accumulation of mature Cε
transcripts, the mechanism of rsFcεRIα-induced inhibition
of IgE synthesis can be at least partly explained by the
decrease in IL-6 production by IgE-expressing B cells.
Our observation that F(ab′ )2 but not Fab fragment of
anti-IgE mAb inihibited mature Cε transcription and IgE
synthesis is in accordance with a previous report describ-
ing that a cross-linking of surface IgE was required for the
inhibitory activity.4 An interesting finding was that the
F(ab′ )2 fragment induced apoptosis in IgE-expressing B
cells through surface IgE cross-linking. This finding is in
line with several reports19–21 showing that mature B cell
subsets, including germinal center and memory B cells,
undergo apoptosis upon subsequent ligation of surface
Ig. Because surface IgM ligation has been shown to
induce caspase-dependent and -independent apoptosis,
the apoptotic pathways coupled to the surface IgE may
involve activation of pro-apoptotic signals, including
effector caspases.21,22 The apoptotic cell induction we
found was seen in approximately 50% of IgE-expressing
cells, but the remainder were resistant to surface IgE-
mediated apoptosis. Nevertheless, mature Cε transcrip-
tion was markedly inhibited by the F(ab′ )2 fragment.
Therefore, it is likely that additional events, which are
independent of cell death by apoptosis, are also involved
in the regulation of IgE synthesis. One possible event is
that apoptosis-resistant IgE-expressing B cells may have
fallen into anergy after divalent recognition. Similar phe-
nomena have been obtained with IgE memory B cells,
which can be specifically inactivated by treatment with
anti-IgE antibodies, resulting in abrogation of secondary
IgE responses.23,24 Collectively, inhibition of IgE synthesis
by anti-IgE mAb is most likely due to the combination of
surface IgE-mediated apoptosis and anergy in IgE-
expressing B cells.
Although the anti-IgE mAb used in the present study is
anaphylactogenic, non-anaphylactogenic humanized or
chimeric anti-IgE mAbs have been produced that bind to
free IgE and surface IgE on B cells but not to IgE bound
to FcεRI or FcεRII/CD23 on various cell types.25–29 These
properties are similar to those of rsFcεRIα, which traps
IgE via its Cε3 domain, responsible for receptor binding.
The non-anaphylactogenic anti-IgE mAbs reduced serum
levels of free IgE in atopic patients to low or almost
undetectable levels. This reduction is rapid, which is due
predominantly to the formation of complexes with IgE.
Anti-IgE therapy has also been shown to inhibit allergic
inflammation and to improve symptoms.26,28,29 Similar
results have been obtained with rsFcεRIα in experimental
animal models.6,7,30 In addition to such pharmacologic
modulation of IgE-mediated responses, anti-IgE mAb
and rsFcεRIα selectively inhibit IgE synthesis by binding to
surface IgE on B cells, although their immunoregulatory
mechanisms are entirely different. Thus, it is also expected
from previous and present studies that anti-IgE mAb or
rsFcεRIα treatment of atopic patients may eliminate the
terminal differentiation of IgE-expressing B cells, including
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memory cells, into IgE-secreting cells, with ameliorated
effects on allergic symptoms.
In summary, we have shown that monovalent recogni-
tion of surface IgE by rsFcεRIα, but not by Fab fragment
of anti-IgE mAb, leads to a decrease in IL-6 production by
IgE-expressing B cells and that divalent recognition by the
F(ab′)2 fragment induces apoptosis in the cells. It is clear
from these findings that regulation of IgE synthesis by
rsFcεRIα differs from that by anti-IgE mAb. Further studies
are needed to define the nature of the putative factors
conferring inhibition of IL-6 secretion by rsFcεRIα or
induction of apoptosis by anti-IgE mAb in IgE-expressing
B cells.
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